Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
暂无分享,去创建一个
B. Cho | E. Shin | S. Park | S. Park | Y. Kim | H. I. Yoon | K. Pyo | M. Hong | H. Kim | C. Kim | S. J. Choi | B. Ahn | K. H. Kim | H. Shim | Chun-Feng Xin | J. G. Lee | C. -. Lee | S. Choi
[1] D. Planchard,et al. Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.
[2] J. Soria,et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management , 2018, Nature Reviews Clinical Oncology.
[3] V. Torri,et al. Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade , 2018, Clinical Cancer Research.
[4] E. Ruppin,et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.
[5] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[6] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[7] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[8] A. Dicker,et al. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth , 2017, Oncoimmunology.
[9] V. Servois,et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[11] Razelle Kurzrock,et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.
[12] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[13] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[14] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[15] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[16] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[17] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[19] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[20] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[21] G. Brodeur,et al. Mechanisms of neuroblastoma regression , 2014, Nature Reviews Clinical Oncology.
[22] T. Okazaki,et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.
[23] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[24] G. Belz,et al. Effector and memory CD8+ T cell differentiation: toward a molecular understanding of fate determination. , 2010, Current opinion in immunology.
[25] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.